Both abstracts provide the latest insights into the clinical use of focal laser ablation for prostate cancer, contributing to the ongoing development of minimally invasive cancer therapies.

On the 29th of August, CLS organized a training camp for our European distributors within urology and their Clinical Applications Specialists. During two intense days in Turin, Italy, the team learned a lot about the treatment of localized prostate cancer using the CLS TRANBERG® product portfolio, both in theory and in practice.

Now, when summer is approaching and we're all looking forward to enjoying some days off, it's time to sumarize the news from the first half of 2024.

The Imperial Prostate Masterclass meeting in London brings together key opinion leaders in urology and experts in focal therapy from around the world. AS part of the program CLS hosted a hands-on training session.

For CLS it has been an intense start to the year with many positive news. Read about what has been happening with a focus on actions to future proof our core technology, an update on market expansion, andew company presentations.

For CLS this meeting offered a perfect opportunity to meet with both the leading experts, and with clinicians about to introducing focal therapy in their clinic.

Learn about our progress within the Mobile Service Provider Model enabling more clinics to treat prostate cancer patients.

Listen to a podcast episode with Michael Magnani, President of CLS Americas and Dr Garrett D. Pohlman, urologist at Kearney and the host of the Prostate Health Podcast. They had an engaging discussion around the key features and benefits of using the TRANBERG system for the treatment of low to intermediate localized prostate cancer.

This month, men all around the world are growing mustaches to raise awareness for men's health issues, such as prostate cancer, testicular cancer, mental health, and suicide prevention. It's more than just a mustache; it's a movement to make a difference in the lives of men everywhere.

In this edition of our newsletter, you can read more about CLS’s commercial and medical milestone that was achieved at AVANT Concierge Urology in the US, and exhibitions where our TRANBERG® system and the ClearPoint Prism™ system, powered by CLS, have been demonstrated. We are also proud to present three new members that will strengthen the CLS team.

With his long experience from the medical device and healthcare sectors, Jimmy Johansson has been a great asset to CLS since 2015. Among other things, Jimmy was the project manager behind the development of Thermoguide™ Workstation, our tool for monitoring and control of MRI-guided laser ablation. In May this year Jimmy was appointed CLS´s Executive VP Operations. This is a new coordinating management function created to streamline our operations and secure the company’s continued growth. We caught up with Jimmy to hear more. Joel has shared his journey with CLS. Let’s hear what he said.

Watch our new video from a patient case to get an insight into how physicians can monitor a laser ablation procedure in near real time.

We are happy to introduce Joel Hix, Director of Clinical Operations at CLS Americas. Joel has over 15 years of senior management experience in operations, sales, marketing, and service with leading medical device manufacturers including Boston Scientific and Healthtronics.

For the first time results from the CLS-sponsored study at Skåne University Hospital (SUS) will be presented and discussed during an international scientific congress. We are happy to share the abstract OP033 “Laser interstitial thermal therapy using an uncooled laser catheter in a diagnostic MR suite” by Dr Hjalmar Bjartmarz et al.

We are happy to share that CLS Americas has entered into an agreement with Genesis Research, LLC, an affiliate of Unio Health Partners, to conduct a Phase I clinical study titled, “Micro Ultra-Sound Guided, Transperineal Focal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer.”

Under the agreement, NIHCC will access the clinical utility of the CLS’s TRANBERG® Thermal Therapy System towards MRI/Ultrasound fusion-guided focal laser ablation (FLA) of prostate tissue and prostate cancer in male patients.

We are proud to release a detailed video animation of the minimally invasive, fusion-guided, focal laser ablation (FLA) of a prostate tumor using the TRANBERG™ Thermal Therapy System.

We are happy to share that HALO Diagnostics, Inc. (HALO Dx) will evaluate the safety and short term efficacy of CLS’s TRANBERG® Thermal Therapy System for treating low-to-medium risk prostate cancer patients.

Since CLS´s laser ablation system for neurosurgery was cleared by the FDA in September last year development has progressed rapidly. But how does it actually work? We explain in this news post.

Today Skåne University Hospital (SUS) published a press release with the title “Laser surgery in a magnetic camera – new help for patients with brain tumors”. The PM provides an insight to the ongoing study using CLS products for laser surgery inside a MRI camera. The hospital writes that doctors now can treat patients with hard-to-reach brain tumors that medical care was previously unable to help. So far two patients with brain tumors have been successfully treated as part of the study.

Dr Eric Walser is an internationally recognized interventional radiologist with extensive clinical experience of using non-surgical ablation for the treatment of small tumors as an alternative to traditional surgery. Dr Eric Walser uses the TRANBERG® Thermal Therapy System to treat localized prostate cancer in clinical practice.

CLS today announced that the first patient has been safely treated in the clinical trial at Skåne University Hospital (SUS) aiming to evaluate MR-guided Laser Interstitial Thermal Therapy (MRg LITT) for glioblastoma ablation.

The RSNA (Radiological Society of North America) annual meeting is ongoing in Chicago, the US. Yesterday, interim data from the ongoing study in Toronto using CLS´s TRANBERG products, was presented by the principal investigator MD Sangeet Ghai.   

We are happy to announce that our Chief Technology Officer Cristina Pantaleone today has been awarded Technician of the Year by the Chamber of Commerce and Industry of Southern Sweden.

We want to highlight a couple of scientific presentations held during the 13th Interventional MRI Symposium 2022 in Leipzig, October 14-15, 2022. This event provides an ideal platform for researchers, clinicians, and healthcare professionals alike to present their latest results within interventional MRI.

Our CTO Cristina Pantaleone and VP Medical Affairs Hoda Tawfik, explain how the TRANBERG® Thermal Therapy Systems have been designed for precise and safe focal therapy of soft tissue, such as the prostate gland, and what kind of research CLS is now supporting.

CEO Dan J. Mogren introduces our support for Movember. This annual campaign is all about raising awareness around male health, and specifically around prostate cancer. It is one of the most common cancer forms among men, but more can be done to spread knowledge about the disease.

Combined products enable minimally-invasive, high precision laser focal therapy of prostate tumors in an office or clinic. CLS Americas and Focalyx Technologies, today announced the companies will exhibit and demonstrate their respective products.

We are proud to announce that CLS has received FDA 510(k) clearance for our MR guided laser ablation system in neurosurgery!

The first patient will shortly be treated with the CLS laser ablation system in a sponsored study at Skåne University Hospital. The Swedish medical journal Läkartidningen now reports from the hospital.

We are now in the final preparations for the Imperial Prostate Masterclass meeting in London taking place this week. This is a small meeting, but this is also where we well meet the leading specialists and KOLs in the field.

The CLS team is looking forward to showcasing our new product generation towards urologists and radiologists through a variety of activities during the coming autumn...

CEO Dan J. Mogren is presenting CLS at Biostock Life Science spring summit 2022. Watch the full presentation here.

SVTs lokalnyheter sände i tisdags ett reportage från Skånes universitetssjukhus där patienter opereras inne i en magnetkamera. Så kommer det också gå till när Skånes universitetssjukhus inleder laserablationsbehandlingar av hjärntumörer - med CLS system.

CLS och Skånes Universitetssjukhus ser fram mot den kommande kliniska studie där CLS system för laserablation kommer utvärderas för behandling av patienter med tumörsjukdomen glioblastom.

CLS has entered an agreement with Quadia Diagnostic Imaging Center in Piaseczno, Poland on a commercial evaluation of its second-generation TRANBERG® Thermal Therapy System with Thermoguide™ Workstation in MR-guided stereotactic focal laser ablation of localized prostate cancer.

CLS Americas today announced the first patient has been safely treated in its recently announced 20-patient, Phase I clinical study.

CLS is looking forward to participating in the annual European Conference on Interventional Oncology (ECIO) 2022, April 24-27 in Vienna, Austria. The meeting is the world’s most comprehensive platform for education and knowledge exchange within interventional oncology with over 1 450 international delegates attending.

Clinical Laserthermia Systems AB, today announced the company’s TRANBERG® Thermal Therapy System will be used by Focalyx Technologies, developer of image-guided fusion target devices, to conduct a 20-patient, Phase I clinical study titled, “Targeted MRI/ US Fusion Transperineal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer.”

Radboud University Medical Center (Radboudumc) in Nijmegen in the Netherlands has obtained approval from its ethics committee for its Investigator Initiated Trial (IIT) to evaluate the safety and feasibility of magnetic resonance guided focused laser ablation (MRgFLA) as a focal therapy treatment for localized prostate cancer in low to intermediate risk patients, using the TRANBERG® Thermal Therapy System with Thermoguide™ Workstation.

CLS and Skåne University Hospital enter a clinical trial agreement to evaluate laser ablation in glioblastoma patients Clinical Laserthermia Systems AB (publ) (CLS), which develops advanced innovative products for high-precision image guided laser ablation, announces that it has entered into an agreement with Skåne University Hospital to sponsor a clinical trial evaluating the safety and feasibility of […]